Acutaas Chemicals Moat Analysis: Score & Risks
Acutaas Chemicals Ltd.
A first-pass moat teardown of Acutaas Chemicals Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Acutaas Chemicals Ltd. scores 5.48 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“2 of these 3 products are very niche and complex, and we have been able to develop an indigenous process, which is not only better in terms of cost, efficiency and yield, but also environmental friendly.”
“22+ Process Patents (5 patents published; 10 patents granted, and 7 patents applied)”
“Company has been significantly growing this business segment with introduction of large CDMO contracts to balance the business model.”
“On the semiconductor business side, the seeding is going on. We are targeting or we are expanding our reach into newer geography of Taiwan, Korea and Japan.”
“Starting with pharmaceutical intermediates: The demand have been slowly improving but what is more painful is the pricing, the pricing for the generic intermediates have been at their lowest.”
“Certifications from global regulators such as USFDA, PMDA”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion